High quality, internationally proven biosimilar diabetic therapy BASALOG ONE® OFFERS CONVENIENT AND LOWER COST TREATMENT FOR DIABETES PATIENTS
Kuala Lumpur November 27, 2018 – High quality, internationally proven biosimilar diabetic therapy that is cost effective can effectively substitute ‘branded’ innovator drugs in reducing the burden on public health and paying patients to manage the cost of treating diabetes in Malaysia, which has the highest number of diabetics in the Asean region.